BiondVax Pharmaceuticals Ltd.
BVXV · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $3 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $10 | $16 | $69 |
| G&A Expenses | $0 | $24 | $16 | $9 |
| SG&A Expenses | $5 | $24 | $5 | $9 |
| Sales & Mktg Exp. | $0 | $0 | -$11 | $0 |
| Other Operating Expenses | $0 | $1 | -$23 | $0 |
| Operating Expenses | $11 | $35 | -$2 | $78 |
| Operating Income | -$11 | -$35 | $1 | -$78 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | -$5 | -$2 | -$31 |
| Pre-Tax Income | -$6 | -$40 | -$1 | -$109 |
| Tax Expense | -$5 | $11 | -$8 | $15 |
| Net Income | -$1 | -$51 | $7 | -$124 |
| % Margin | – | – | – | – |
| EPS | -0.2 | -36 | 6.15 | -151.98 |
| % Growth | 99.4% | -685.4% | 104% | – |
| EPS Diluted | -0.2 | -36 | 6.15 | -151.98 |
| Weighted Avg Shares Out | 3 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 3 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $0 | $1 | $0 |
| Interest Expense | $0 | $11 | $5 | $15 |
| Depreciation & Amortization | $1 | $2 | $2 | $1 |
| EBITDA | -$10 | -$27 | $6 | -$93 |
| % Margin | – | – | – | – |